
Celcuity Inc
Biotechnology
Celcuity Inc (CELC) Stock News
The latest CELC headlines and market coverage — 2 recent stories, updated throughout the day.
- GlobeNewswire Inc.·
NASDAQ: CELC Investigation: Kessler Topaz Meltzer & Check, LLP Encourages Celcuity Inc. (NASDAQ: CELC) Investors to Contact the Firm
Law firm Kessler Topaz Meltzer & Check is investigating Celcuity Inc. for potential securities law violations following the company's announcement of a delayed drug launch for its FDA-approved breast cancer therapy Revtorpyk. The delayed launch timeline, announced on July 14, 2026, fell short of analyst expectations and triggered a 17% stock price decline. The firm is encouraging investors who suffered losses to contact them regarding potential legal rights.
- GlobeNewswire Inc.·
CELCUITY ALERT: Bragar Eagel & Squire, P.C. is Investigating Celcuity Inc. on Behalf of Celcuity Stockholders and Encourages Investors to Contact the Firm
Law firm Bragar Eagel & Squire is investigating Celcuity Inc. for potential securities violations following the company's announcement of FDA approval for breast cancer therapy Revtorpyk with a delayed commercial launch in late Q3 2026. The delayed timeline, contrary to analyst expectations, triggered a 17.6% stock price decline on July 15, 2026.